JP6333026B2 - Nitric oxide scavenger - Google Patents
Nitric oxide scavenger Download PDFInfo
- Publication number
- JP6333026B2 JP6333026B2 JP2014074646A JP2014074646A JP6333026B2 JP 6333026 B2 JP6333026 B2 JP 6333026B2 JP 2014074646 A JP2014074646 A JP 2014074646A JP 2014074646 A JP2014074646 A JP 2014074646A JP 6333026 B2 JP6333026 B2 JP 6333026B2
- Authority
- JP
- Japan
- Prior art keywords
- nitric oxide
- extract
- oxide scavenger
- present
- radical scavenging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940088382 Nitric oxide scavenger Drugs 0.000 title claims description 11
- 239000000284 extract Substances 0.000 claims description 13
- 241000722941 Achillea Species 0.000 claims description 7
- 241001442129 Myosotis Species 0.000 claims description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 100
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000419 plant extract Substances 0.000 description 9
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- BPBUJYBQUBMWDT-VQHVLOKHSA-N (E)-hydroxyimino-[methyl-[3-(methylamino)propyl]amino]-oxidoazanium Chemical compound CNCCCN(C)[N+](\[O-])=N/O BPBUJYBQUBMWDT-VQHVLOKHSA-N 0.000 description 5
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 206010040070 Septic Shock Diseases 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 4
- 230000036303 septic shock Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101100278667 Drosophila melanogaster Duox gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000002803 fossil fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229940092385 radish extract Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Description
本発明は、ユリ科ワスレグサ属に属するアキノワスレグサの抽出物を含有する安全性の高い一酸化窒素(以下、「NO」と言う場合がある。)消去剤に関する。更に詳しくは、NO産生亢進に起因する皮膚疾患、冠動脈硬化、狭心症、心不全、高血圧、動脈硬化、敗血症性ショック、肝硬変、腎不全、炎症性疾患などの疾患症状に対する予防薬・治療薬として有用な医薬品、食品、化粧品組成物に関する。 The present invention relates to a highly safe nitric oxide (hereinafter, sometimes referred to as “NO”) scavenger containing an extract of Aquinowaceae belonging to the genus Forget-me-not. More specifically, as a prophylactic / therapeutic agent for diseases such as skin diseases caused by increased NO production, coronary arteriosclerosis, angina pectoris, heart failure, hypertension, arteriosclerosis, septic shock, cirrhosis, renal failure, inflammatory diseases, etc. The present invention relates to useful pharmaceuticals, foods, and cosmetic compositions.
活性酸素の一つであるNOは、大気汚染物質として問題となっている窒素酸化物(NOx)の一種であり、大気中で酸化されてNO2になる。NO2は、高濃度で呼吸器に影響を及ぼすほか、環境汚染の原因物質の一つだといわれている。また、空気中のNOは、酸化剤として働き、皮脂に含まれる不飽和脂肪酸等を攻撃して、肌荒れ等を引き起こす原因となる可能性も指摘されている(非特許文献1)。 NO which is one of the active oxygens is a kind of nitrogen oxide (NOx) which is a problem as an air pollutant, and is oxidized into NO2 in the atmosphere. NO2 is said to be one of the causative substances of environmental pollution in addition to affecting respiratory organs at high concentrations. In addition, it has been pointed out that NO in the air may act as an oxidant, attacking unsaturated fatty acids contained in sebum, and causing rough skin (Non-Patent Document 1).
NOの発生原因は、主として石油等の化石燃料の燃焼によるものであり、工場、自動車、家庭等から排出されている。また、より身近な例としてタバコの煙中にも存在することが知られている(非特許文献2)。 The cause of NO generation is mainly due to the combustion of fossil fuels such as oil, and is emitted from factories, automobiles, homes and the like. Moreover, it is known that it exists also in the smoke of tobacco as a more familiar example (nonpatent literature 2).
一方、NOは生体内にも存在することも知られている。生体内のNOは、L−アルギニン、NADPH、テトラヒドロビオプテリン、カルモジュリン等を基質としてNO合成酵素(以下、NOSという)により作られ、極めて重要な生理活性分子として機能している。例えば、血管内皮由来弛緩因子(EDRF)の正体はNOであり、その他、神経系における情報伝達物質や免疫系での異物攻撃の役割を担っていることが知られている。 On the other hand, it is also known that NO exists in the living body. In vivo, NO is produced by NO synthase (hereinafter referred to as NOS) using L-arginine, NADPH, tetrahydrobiopterin, calmodulin and the like as a substrate, and functions as an extremely important physiologically active molecule. For example, the true identity of vascular endothelium-derived relaxing factor (EDRF) is NO, and it is also known that it plays a role of a foreign body attack in the information system in the nervous system and in the immune system.
NOは発見当初から主として血流保持作用の観点により常に細胞保護的に作用していると考えられてきたが、高濃度のNOは細胞障害性を有することや人体の病態に悪影響を与えることが報告されている。NOの産生過剰状態としてエンドトキシンショック、動脈硬化症の存在が明らかにされてきた。そのほかにも心不全、心筋炎、敗欠症性ショック、肝硬変など多くの病態におけるNOの関与が報告されている(非特許文献3)。 Although NO has been considered to always act in a cytoprotective manner mainly from the viewpoint of blood flow retention action from the beginning of its discovery, high concentrations of NO may have cytotoxicity or adversely affect human pathology. It has been reported. The existence of endotoxin shock and arteriosclerosis has been clarified as an overproduction state of NO. In addition, the involvement of NO in many pathological conditions such as heart failure, myocarditis, septic shock, and cirrhosis has been reported (Non-patent Document 3).
過剰に産生された生体内NOを低減する手段として、Nω−モノメチル−L−アルギニン、Nω−ジメチル−L−アルギニン、Nω−ニトロ−L−アルギニン等のL−アルギニン誘導体やアミノグアニジンやS−エチルイソチオウレア等のアルギニン類似化合物のようなNOSを不活性化するNOS阻害剤やジエチレントリアミン5酢酸の鉄錯体、デスフェリオキサミンの鉄錯体、ヒドロキソコバラミン等のようなNOと速やかに反応するNO消去剤等の使用が挙げられる(非特許文献4)。 L-arginine derivatives such as Nω-monomethyl-L-arginine, Nω-dimethyl-L-arginine, Nω-nitro-L-arginine, aminoguanidine and S-ethyl NOS inhibitors that inactivate NOS, such as arginine analogs such as isothiourea, NO scavengers that react rapidly with NO, such as iron complexes of diethylenetriaminepentaacetic acid, iron complexes of desferrioxamine, hydroxocobalamin, etc. (Non-Patent Document 4).
しかしながら、上記のようなNOS阻害剤を投与した臨床的な試みにおいては、症状の改善にはつながるものの、NO合成の制御では生成するNOの定量的制御が難しく、血圧の上昇、臓器の血流低下・障害等の様々な副作用を引き起こすという問題が指摘されている。また、上記のような従来のNO消去剤は選択的にNOを消去することに注力したものではなかった。 However, in clinical trials in which a NOS inhibitor as described above is administered, although it leads to improvement of symptoms, it is difficult to quantitatively control NO produced by controlling NO synthesis, resulting in increased blood pressure, organ blood flow. Problems have been pointed out that cause various side effects such as reduction and disability. Further, the conventional NO erasing agent as described above has not been focused on selectively eliminating NO.
これまで活性酸素は生体内のエネルギー代謝や感染防御過程において発生する一連の反応性分子種(O2 −,H2O2等)であり、これまで酸素毒性の要因となる有害物質として取り扱われてきた(活性酸素毒性説)。 Previously active oxygen range of reactive species generated in the energy metabolism and infection protective process in vivo (O 2 -, H 2 O 2 , etc.), and treated as hazardous substances that cause oxygen toxicity far (Active oxygen toxicity theory).
一方、生体内には Nox(およびDuox)と呼ばれる酵素群があり、白血球の抗菌作用のみならず、血管系、上皮・内分泌系細胞やリンパ球など多彩な細胞において積極的に活性酸素を産生し、殺菌作用以外の生理機能を発揮していることが近年報告されており、活性酸素は生体内で細胞保護シグナルとして重要な情報伝達も司っている(非特許文献5)。 On the other hand, there is an enzyme group called Nox (and Duox) in the living body that actively produces active oxygen not only in the antibacterial action of leukocytes but also in various cells such as vascular, epithelial / endocrine cells and lymphocytes. In recent years, it has been reported that physiological functions other than bactericidal action are exerted, and active oxygen also controls important information transmission as a cell protection signal in vivo (Non-patent Document 5).
このように、活性酸素は細胞・組織において、大変重要なシグナル機能も担っていることがわかってきた。そのため、身体に悪影響を及ぼす危険性があるNOの産生過剰状態を、従来の抗酸化物質を用いて改善しようとすると、細胞保護シグナルのような生体にとって重要な働きを担っている活性酸素も消去することになってしまう。そのため、他の活性酸素を消去することなく選択的にNOを消去することは大変重要であり、NOに着目した研究は大変意味がある。 Thus, it has been found that active oxygen also has a very important signal function in cells and tissues. Therefore, when trying to improve the overproduction state of NO, which has a risk of adversely affecting the body, using conventional antioxidants, the active oxygen that plays an important role for the living body such as cytoprotective signals is also eliminated. Will end up. For this reason, it is very important to selectively erase NO without erasing other active oxygen, and research focusing on NO is very meaningful.
本発明は、選択的にNOを消去する高い活性を有する物質の提供を課題としている。 An object of the present invention is to provide a substance having high activity for selectively eliminating NO.
本願発明は活性酸素種のなかでも、とりわけ一酸化窒素を選択的に消去する成分を有効成分とするものである。
具体的には、アキノワスレグサ抽出物を有効成分として含有させて、一酸化窒素消去剤を用いることで上記課題を解決する。本願一酸化窒素消去剤は、そのまま或いは、飲食品、医薬品、又は化粧品に添加して用いることもできる。
In the present invention, among active oxygen species, a component that selectively eliminates nitric oxide is an effective component.
Specifically, the above-mentioned problem is solved by using an extract of Achillea regusa as an active ingredient and using a nitric oxide scavenger. The present nitric oxide scavenger can be used as it is or in addition to foods, drinks, pharmaceuticals, or cosmetics.
本願発明の一酸化窒素消去剤は、NO産生亢進に起因する皮膚疾患および冠動脈硬化、狭心症、心不全、高血圧、動脈硬化、敗血症性ショック、肝硬変、腎不全、炎症性疾患などの疾患症状に対する予防薬・治療薬として有用な医薬品、食品、化粧品組成物としても有用である。 The nitric oxide scavenger of the present invention is for skin diseases caused by increased NO production and disease symptoms such as coronary arteriosclerosis, angina pectoris, heart failure, hypertension, arteriosclerosis, septic shock, cirrhosis, renal failure, and inflammatory diseases. It is also useful as a pharmaceutical, food or cosmetic composition useful as a preventive or therapeutic agent.
本発明に用いるアキノワスレグサは、ユリ科ワスレグサ属の多年草植物で、別名「萱草」、「金針」、「忘憂草」等と称される。使用する部位は特に限定されない。全草の他、花、葉、茎、根、蕾、種子等が使用できる。 The Achillea forget-me-not used in the present invention is a perennial plant belonging to the genus Forget-me-not. The site to be used is not particularly limited. In addition to whole plants, flowers, leaves, stems, roots, pods, seeds, etc. can be used.
アキノワスレグサ抽出物の調製方法は特に限定されないが、例えば種々の適当な有機溶媒を用いて、低温下から加温下で抽出される。抽出溶媒としては、例えば、水;メチルアルコール、エチルアルコール等の低級1価アルコール;グリセリン、プロピレングリコール、1,3−ブチレングリコール等の液状多価アルコール;アセトン、メチルエチルケトン等のケトン;酢酸エチルなどのアルキルエステル;ベンゼン、ヘキサン等の炭化水素;ジエチルエーテル等のエーテル類;ジクロルメタン、クロロホルム等のハロゲン化アルカン等の1種または2種以上を用いることができる。就中、水、エチルアルコール、1,3−ブチレングリコールの1種または2種以上の混合溶媒が特に好適である。 Although the preparation method of an Aquinoa legusa extract is not specifically limited, For example, it extracts under low temperature from heating using various suitable organic solvents. Examples of the extraction solvent include water; lower monohydric alcohols such as methyl alcohol and ethyl alcohol; liquid polyhydric alcohols such as glycerin, propylene glycol, and 1,3-butylene glycol; ketones such as acetone and methyl ethyl ketone; and ethyl acetate. One type or two or more types of alkyl esters; hydrocarbons such as benzene and hexane; ethers such as diethyl ether; halogenated alkanes such as dichloromethane and chloroform can be used. Among them, water, ethyl alcohol, and a mixed solvent of one or more of 1,3-butylene glycol are particularly suitable.
本発明に用いることのできる植物抽出物の抽出方法は特に限定されないが、例えば乾燥したものであれば質量比で1〜1000倍量、特に10〜100倍量の溶媒を用い、0℃以上、特に20℃〜40℃で1時間以上、特に3〜7日間行うのが好ましい。また、60〜100℃で1時間、加熱抽出しても良い。 Although the extraction method of the plant extract which can be used for this invention is not specifically limited, For example, if it is dried, it is 1-1000 times amount by mass ratio, especially 10-100 times amount of solvent, 0 degreeC or more, In particular, it is preferably performed at 20 ° C. to 40 ° C. for 1 hour or longer, particularly 3 to 7 days. Moreover, you may heat-extract at 60-100 degreeC for 1 hour.
以上のような条件で得られる上記各抽出物は、抽出された溶液のまま用いても良いが、さらに必要により、濾過等の処理をして、濃縮、粉末化したものを適宜使い分けて用いることができる。 Each of the above-mentioned extracts obtained under the above conditions may be used as an extracted solution, but if necessary, use a product that has been subjected to a treatment such as filtration, concentrated and powdered as appropriate. Can do.
本発明の一酸化窒素消去剤における植物抽出物の配合量は、有効量存在すれば良い。
一般的には一酸化窒素消去剤の組成物に対して蒸発乾燥分に換算して0.0001〜100質量%が好ましく、特に0.01〜10.0質量%の範囲が最適である。
The effective amount of the plant extract in the nitric oxide scavenger of the present invention may be present.
Generally, it is preferably 0.0001 to 100% by mass in terms of the evaporated and dried content with respect to the composition of the nitric oxide scavenger, and particularly the range of 0.01 to 10.0% by mass is optimal.
本発明の一酸化窒素消去剤の剤型は特に限定されない。液状、ジェル状、粉末状、乳化状等各種の剤型で用いることができる。 The dosage form of the nitric oxide scavenger of the present invention is not particularly limited. Various dosage forms such as liquid, gel, powder, and emulsion can be used.
本発明の一酸化窒素消去剤は、本発明の一酸化窒素消去剤を基剤に配合して製造することができる。本発明の一酸化窒素消去剤以外に、本発明の効果を損なわない範囲で、たとえば、油脂、ロウ類、炭化水素油、エステル油、高級アルコール、シリコーン油、紫外線吸収剤、紫外線散乱剤、保湿剤、界面活性剤、水溶性高分子、増粘剤、粉体、各種有効成分、皮膚保護剤、老化防止剤、植物抽出物、防腐剤、消炎剤、pH調整剤、金属イオン封鎖剤、酸化防止剤などを配合することができる。 The nitric oxide scavenger of the present invention can be produced by blending the nitric oxide scavenger of the present invention into a base. In addition to the nitric oxide scavenger of the present invention, as long as the effects of the present invention are not impaired, for example, fats and oils, waxes, hydrocarbon oils, ester oils, higher alcohols, silicone oils, ultraviolet absorbers, ultraviolet scattering agents, moisturizing agents. Agent, surfactant, water-soluble polymer, thickener, powder, various active ingredients, skin protectant, anti-aging agent, plant extract, antiseptic, anti-inflammatory agent, pH adjuster, sequestering agent, oxidation An inhibitor or the like can be blended.
以下、本発明を実施例によりさらに具体的に説明するが、本発明はこれらの実施例により限定されるものではない。また、特記しない限り配合量は質量%で示す。 EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to these examples. Unless otherwise specified, the blending amount is expressed in mass%.
<被験物質の調製>
(1)被検物質の植物抽出物は、アキノワスレグサ(葉及び茎の混合物)、夏枯草(葉及び茎の混合物)、ウラジロガシ(葉)の乾燥物を用いて調製した。各植物原体1gに10倍量の50%エタノールを10g加えて60℃、3時間加熱抽出した。抽出後、ろ過をし、植物原体を取り除いた後、固形蒸発残分が1%になるように蒸留水で希釈した。以上の操作によって、固形蒸発残分が1%になるように調製した植物抽出物を得た。
(2)アスコルビン酸、Trolox(6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸)、BHT(ジブチルヒドロキシトルエン)はDMSO(ジメチルスルホキシド)で溶解させ、全て10 mMの濃度に調製した。
<Preparation of test substance>
(1) The plant extract of the test substance was prepared by using a dried product of Akinowasusa (a mixture of leaves and stems), summer hay (a mixture of leaves and stems), and radish (leaves). 10 g of 50% ethanol of 10 times the amount was added to 1 g of each plant raw material and extracted by heating at 60 ° C. for 3 hours. After extraction, the mixture was filtered to remove the plant material, and diluted with distilled water so that the solid evaporation residue was 1%. By the above operation, a plant extract prepared so that the solid evaporation residue was 1% was obtained.
(2) Ascorbic acid, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) and BHT (dibutylhydroxytoluene) were dissolved in DMSO (dimethyl sulfoxide), and all were 10 mM. Concentration was adjusted.
DPPHラジカル捕捉試験
既知の抗酸化物質と植物抽出物のラジカル捕捉能を確認するため、DPPHラジカル捕捉試験を用いて、ラジカル捕捉能の評価を行なった。
(1)MES(2−モルホリノエタンスルホン酸)8.53gをdH2O 100mLで溶解し、400mM MESを調製した。
(2)DPPH(1,1−ジフェニル−2−ピクリルヒドラジル)0.0628gをEtOH 100 mL で溶解し、0.4mM DPPHを調製した。
(3)DPPH:MES:dH2O=4:1:3の割合で混合し、これをDPPH Working Solutionとして調製した。
(4)96穴マイクロプレートに上述の方法で調製した植物抽出物10μLを分注し、DPPH Working solutionを190μL添加し、プレートミキサーで30分振とうさせた。
(5)その後、マイクロプレートリーダーで540nmの吸光度を測定した。測定後、下記のラジカル捕捉率の計算式を用いて算出した。結果は図1に示す。尚、植物抽出物は植物名のみ表記している。
DPPH radical scavenging test In order to confirm the radical scavenging ability of known antioxidants and plant extracts, the DPPH radical scavenging test was used to evaluate the radical scavenging ability.
(1) 8.53 g of MES (2-morpholinoethanesulfonic acid) was dissolved in 100 mL of dH2O to prepare 400 mM MES.
(2) 0.0628 g of DPPH (1,1-diphenyl-2-picrylhydrazyl) was dissolved in 100 mL of EtOH to prepare 0.4 mM DPPH.
(3) DPPH: MES: dH2O = 4: 1: 3 was mixed, and this was prepared as DPPH Working Solution.
(4) 10 μL of the plant extract prepared by the above method was dispensed to a 96-well microplate, 190 μL of DPPH Working solution was added, and the plate was shaken for 30 minutes with a plate mixer.
(5) Thereafter, the absorbance at 540 nm was measured with a microplate reader. After the measurement, it was calculated using the following formula for calculating the radical scavenging rate. The results are shown in FIG. In addition, only the plant name is described in the plant extract.
ラジカル捕捉率の計算式
(1)10mM Troloxを調製し、それをDMSOで段階希釈し、標準試薬として用いた。
(2)上記の段階希釈したTroloxの吸光度Ab540の値と濃度から検量線(Y=aX+b、Y=吸光度、X=濃度)を作成した。
(3)その検量線Y=aX+bから、試料のTrolox当量として濃度を算出した。
<式1>
Trolox当量=(測定試料Ab540−b)/a(mM)
Formula for calculating radical scavenging rate (1) 10 mM Trolox was prepared, serially diluted with DMSO, and used as a standard reagent.
(2) A calibration curve (Y = aX + b, Y = absorbance, X = concentration) was prepared from the values and concentrations of the Trolox absorbance Ab540 of the above serial dilution.
(3) From the calibration curve Y = aX + b, the concentration was calculated as the Trolox equivalent of the sample.
<
Trolox equivalent = (measurement sample Ab540-b) / a (mM)
既知の抗酸化物質であるアスコルビン酸、BHTでは、高いラジカル捕捉能が確認され、10mMのときそれぞれTrolox当量が8.5mM、5.7mMであった。ウラジロガシ抽出物、夏枯草抽出物も同様にアスコルビン酸、BHTと同等の高いラジカル捕捉能が確認されたが、一方でアキノワスレグサ抽出物は上記の既知の抗酸化物質と比べて非常に低いラジカル捕捉能しか確認されなかった。 Ascorbic acid and BHT, which are known antioxidants, showed high radical scavenging ability, and Trolox equivalents were 8.5 mM and 5.7 mM, respectively, at 10 mM. The radish extract and summer hay extract were also confirmed to have the same high radical scavenging ability as that of ascorbic acid and BHT, while the extract of Achillea grass extract was very low in radical scavenging compared to the above-mentioned known antioxidants. Only the ability was confirmed.
NO消去能評価試験
既知の抗酸化物質と植物抽出物のNO消去能を確認するため、NOの酸化物であるNO2−を測定することでNO量を測定するGriess法を用いて、NO消去能の評価を行なった。Griess法による測定は、NO2/NO3 Assay Kit−CII(Colorimetric)(同仁化学製)を用いた。NO発生剤として、NOC−7(1−ヒドロキシ−2−オキソ−3−(N−メチル-3―アミノプロピル)−3−メチル−1−トリアゼン)(同仁化学社製)を用い、使用直前に0.1N水酸化ナトリウムのアルカリ溶液で調製した。一酸化窒素供与体として開発されたNOC−7はアルカリ溶液中では安定だが、中性および酸性条件下では一酸化窒素を生成する不安定な化合物(25℃、pH7.4条件下で半減期5分)である。
NO scavenging ability evaluation test In order to confirm the NO scavenging ability of known antioxidants and plant extracts, NO scavenging ability is measured using the Griess method, which measures the amount of NO by measuring NO2-an oxide of NO. Was evaluated. For the measurement by the Griess method, NO2 / NO3 Assay Kit-CII (Colorimetric) (manufactured by Dojin Chemical) was used. As NO generator, NOC-7 (1-hydroxy-2-oxo-3- (N-methyl-3-aminopropyl) -3-methyl-1-triazene) (manufactured by Dojin Chemical Co., Ltd.) was used immediately before use. Prepared with an alkaline solution of 0.1N sodium hydroxide. Developed as a nitric oxide donor, NOC-7 is an unstable compound that is stable in alkaline solution but produces nitric oxide under neutral and acidic conditions (half-life of 5 at 25 ° C, pH 7.4). Min).
(1)96穴マイクロプレートにPBSを10μL、上記緩衝液(pH=7.6)を40μL、[0025]で調製した測定試料を10μL添加した。
(2)その後、100μMに調製したNOC−7溶液40μLを添加して、室温で30分反応させた。
(3)反応終了後、Kit中のGriess試薬Aを50μL添加して、続けてGriess試薬Bを50μLずつ添加して10分放置して呈色反応を行った。
(4)マイクロプレートリーダーで540nmの吸光度を測定した。各測定試料における吸光度をS540、試料の代わりに緩衝液とNOC−7のみを混合したコントロールの吸光度をC540、NOC−7を含まないブランクの吸光度をB540として以下の式でNO消去率(%)を算出し、結果を図2に示す。
(1) To a 96-well microplate was added 10 μL of PBS, 40 μL of the buffer solution (pH = 7.6), and 10 μL of the measurement sample prepared in [0025].
(2) Thereafter, 40 μL of a NOC-7 solution prepared to 100 μM was added and reacted at room temperature for 30 minutes.
(3) After completion of the reaction, 50 μL of Griess reagent A in Kit was added, followed by 50 μL of Griess reagent B and left for 10 minutes to perform a color reaction.
(4) Absorbance at 540 nm was measured with a microplate reader. The absorbance in each measurement sample is S540, the absorbance of a control in which only buffer solution and NOC-7 are mixed instead of the sample is C540, and the absorbance of a blank not containing NOC-7 is B540. And the results are shown in FIG.
<式2>
NO消去率(%)={100×(1−(S540−B540)/(C540−B540)}
<Formula 2>
NO erasure rate (%) = {100 × (1− (S540−B540) / (C540−B540)}
抗酸化物質で既知のTroloxはNO抑制率40%と高いNO消去能が観測されたが、ラジカル捕捉能が高い結果を得たBHTやアスコルビン酸の2種においてNO消去能は観測されなかった。一方で、ラジカル捕捉能が観測されなかったアキノワスレグサ抽出物においては、NO抑制率47%と高い結果を得た。
尚、実施例では、アキノワスレグサの葉及び茎の50%エタノール抽出物のみを開示しているが、その他の部位、抽出溶媒においても同様の傾向が見られた。
Trolox, which is known as an antioxidant, was observed to have a high NO scavenging ability with a NO suppression rate of 40%, but NO scavenging ability was not observed in two types of BHT and ascorbic acid that obtained high radical scavenging ability. On the other hand, in the Aquinois regusa extract in which the radical scavenging ability was not observed, a high NO suppression rate of 47% was obtained.
In the examples, only 50% ethanol extract of leaves and stems of Achillea grass is disclosed, but the same tendency was observed in other parts and extraction solvents.
以上の結果から、本発明のアキノワスレグサ抽出物が他の活性酸素種を除くことなく、NOを選択的に消去することが明らかになった。このアキノワスレグサ抽出物は生体内に存在する過剰なNOを選択的に消去し、正常なNO濃度にする作用およびNOが過剰に発生することが予測される場合にあらかじめ投与し生体内に過剰なNOが発生することを防止する作用を有している。従って、NO産生亢進に起因する肌荒れなどの皮膚疾患および冠動脈硬化、狭心症、心不全、高血圧、動脈硬化、敗血症性ショック、肝硬変、腎不全、炎症性疾患などの疾患症状に対する予防薬・治療薬として有用な医薬品、食品、化粧品等に利用することができる。
From the above results, it has been clarified that the extract of Achillea regusa of the present invention selectively eliminates NO without removing other active oxygen species. This extract of Achillea regusa selectively eliminates excess NO present in the living body, and when it is predicted that excessive NO will be generated and the effect of obtaining normal NO concentration, it is excessively administered in the living body. It has the effect of preventing the generation of NO. Therefore, prophylactic / therapeutic agents for skin diseases such as rough skin caused by increased NO production and disease symptoms such as coronary arteriosclerosis, angina pectoris, heart failure, hypertension, arteriosclerosis, septic shock, cirrhosis, renal failure, inflammatory diseases, etc. Can be used for useful pharmaceuticals, foods, cosmetics and the like.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014074646A JP6333026B2 (en) | 2014-03-31 | 2014-03-31 | Nitric oxide scavenger |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014074646A JP6333026B2 (en) | 2014-03-31 | 2014-03-31 | Nitric oxide scavenger |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015196656A JP2015196656A (en) | 2015-11-09 |
JP6333026B2 true JP6333026B2 (en) | 2018-05-30 |
Family
ID=54546592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014074646A Active JP6333026B2 (en) | 2014-03-31 | 2014-03-31 | Nitric oxide scavenger |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6333026B2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4874532B2 (en) * | 2004-08-25 | 2012-02-15 | 株式会社琉球バイオリソース開発 | Sleep improver |
JP2006143670A (en) * | 2004-11-22 | 2006-06-08 | Kyoei Kagaku Kogyo Kk | Skin lotion |
JP5054945B2 (en) * | 2006-08-28 | 2012-10-24 | 共栄化学工業株式会社 | Cosmetics |
KR20100037508A (en) * | 2008-10-01 | 2010-04-09 | 구례군 | Cosmetic composite of containing hemerocallis fulva extract lived in the jirisan |
-
2014
- 2014-03-31 JP JP2014074646A patent/JP6333026B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015196656A (en) | 2015-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3805798B2 (en) | Cosmetics | |
Baghiani et al. | Antioxidants, Free Radicals Scavenging and Xanthine Oxidase Inhibitory Potentials of Ajuga iva L. Extracts. | |
JP2021516669A (en) | Cosmetic composition containing neem leaf extract | |
JP4546790B2 (en) | Lower fatty acid production inhibitor that does not sterilize skin resident bacteria | |
JP6333026B2 (en) | Nitric oxide scavenger | |
JP2012031086A (en) | Antioxidant and cosmetic material | |
JP4179981B2 (en) | Thiol-S-methyltransferase inhibitor, halitosis generation inhibitor, and halitosis generation composition | |
KR20200064384A (en) | Cosmetic composition of antioxidant, anti-inflammatory containing artemisia princeps pampanini | |
JP2005263655A (en) | Antioxidant | |
JP2006249035A (en) | Active oxygen remover | |
JPH06305978A (en) | Tyrosinase inhibitor, beautifying cosmetic and color change preventing agent | |
JP2003335647A (en) | Deodorizer, and drink, food and deodorizing composition containing the same | |
JP2005213202A (en) | Antioxidant, anti-aging agent and antiinflammatory agent, and skin cosmetic | |
JP5004045B2 (en) | Antibacterial agent and antibacterial composition | |
Rekha et al. | Antioxidant activities and GC-MS analysis of ethanol extract of creeper stems of Cissus quadrangularis L. | |
JP5557973B2 (en) | Topical skin preparation | |
CN110269821A (en) | A kind of antiseptic composition and the preparation method and application thereof containing myrtillin chloride | |
Barghout et al. | Polyphenols from Polianthes tuberosa L.(Amaryllidaceae) leaves and their antioxidant properties. | |
JP2013224318A (en) | Active oxygen scavenger, skin care preparation, composition for oral cavity and food product | |
JP4295639B2 (en) | Antioxidant | |
JP2018062481A (en) | Arbutin-containing composition, and method for inhibiting the degradation of arbutin | |
JP5512291B2 (en) | Sebum production inhibitor | |
JP4886878B2 (en) | Tyrosinase activity inhibitor and whitening cosmetic | |
A Akowuah et al. | GC-MS determination of major bioactive constituents and anti-oxidative activities of aqueous extracts of cinnamomum burmannii blume stem | |
WO2021133307A1 (en) | Cosmetic formulation containing the smoke tree extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180417 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180424 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6333026 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |